JP2006502236A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502236A5
JP2006502236A5 JP2004568900A JP2004568900A JP2006502236A5 JP 2006502236 A5 JP2006502236 A5 JP 2006502236A5 JP 2004568900 A JP2004568900 A JP 2004568900A JP 2004568900 A JP2004568900 A JP 2004568900A JP 2006502236 A5 JP2006502236 A5 JP 2006502236A5
Authority
JP
Japan
Prior art keywords
tgf
pharmaceutical composition
disease state
related disease
scleroderma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004568900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003825 external-priority patent/WO2004026307A1/en
Publication of JP2006502236A publication Critical patent/JP2006502236A/ja
Publication of JP2006502236A5 publication Critical patent/JP2006502236A5/ja
Abandoned legal-status Critical Current

Links

JP2004568900A 2002-09-18 2003-09-08 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体 Abandoned JP2006502236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41207902P 2002-09-18 2002-09-18
US48453503P 2003-07-02 2003-07-02
PCT/IB2003/003825 WO2004026307A1 (en) 2002-09-18 2003-09-08 Triazole derivatives as transforming growth factor (tgf) inhibitors

Publications (2)

Publication Number Publication Date
JP2006502236A JP2006502236A (ja) 2006-01-19
JP2006502236A5 true JP2006502236A5 (https=) 2006-10-05

Family

ID=32033582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004568900A Abandoned JP2006502236A (ja) 2002-09-18 2003-09-08 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体

Country Status (25)

Country Link
US (2) US7053095B2 (https=)
EP (1) EP1542685A1 (https=)
JP (1) JP2006502236A (https=)
KR (1) KR20050057393A (https=)
CN (1) CN1681502A (https=)
AP (1) AP2005003260A0 (https=)
AR (1) AR041276A1 (https=)
AU (1) AU2003260810A1 (https=)
BR (1) BR0314577A (https=)
CA (1) CA2497971A1 (https=)
CO (1) CO5540390A2 (https=)
EA (1) EA200500376A1 (https=)
EC (1) ECSP055681A (https=)
HR (1) HRP20050251A2 (https=)
IS (1) IS7713A (https=)
MA (1) MA27442A1 (https=)
MX (1) MXPA05002982A (https=)
NO (1) NO20051010L (https=)
OA (1) OA12927A (https=)
PA (1) PA8583401A1 (https=)
PE (1) PE20050074A1 (https=)
PL (1) PL375974A1 (https=)
TW (1) TW200412346A (https=)
UY (1) UY27981A1 (https=)
WO (1) WO2004026307A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
HRP20050247A2 (en) * 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
JP4547271B2 (ja) * 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子(tgf)阻害剤としての新規イミダゾール化合物
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
KR100910333B1 (ko) * 2005-02-23 2009-07-31 시오노기세이야쿠가부시키가이샤 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체
JP5149177B2 (ja) * 2005-07-25 2013-02-20 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための、チューブリンポリマー化の1,2,3−トリアゾール系抑制剤
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013078286A1 (en) 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
PL3685855T3 (pl) 2012-10-05 2024-04-08 Kadmon Corporation, Llc Ludzkie przeciwciała anty-vegfr-2/kdr
LT2970890T (lt) 2013-03-14 2020-07-10 The Brigham And Women`S Hospital, Inc. Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
US12049475B2 (en) 2018-07-23 2024-07-30 Brise Pharmaceuticals Co., Ltd. Bisphosphonate drug conjugates
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物
JPS6025142A (ja) 1983-07-21 1985-02-07 Matsushita Electric Ind Co Ltd 表示装置の電極製造方法
DE3486009T2 (de) * 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
GB9201692D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
EP0983260A2 (en) 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
DE69821132T2 (de) * 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
JP2000302680A (ja) * 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
JP2004517068A (ja) 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 2−アシルアミノチアゾール誘導体又はその塩
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002062787A1 (en) 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521915A (ja) 2001-02-02 2004-07-22 グラクソ グループ リミテッド Tgf過剰発現に対するピラゾール誘導体
CA2450400A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
WO2004013135A1 (en) 2002-07-31 2004-02-12 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors

Similar Documents

Publication Publication Date Title
JP2006502236A5 (https=)
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
HUS1500021I1 (hu) 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
JP2007523049A5 (https=)
NO20053920D0 (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
PT1611091E (pt) Cristais estáveis de natamicina em forma de agulha
JP2003503454A5 (https=)
JP2005537234A5 (https=)
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
JP2006514116A5 (https=)
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2005507892A5 (https=)
JP2007510667A5 (https=)
JP2008513510A5 (https=)
JP2009518415A5 (https=)
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
JP2009516719A5 (https=)
JP2008513427A5 (https=)
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
JP2008533079A5 (https=)
CL2004001272A1 (es) Compuestos derivados de 3-(4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-1,1-disustituido-urea; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento del compuesto en el tratamiento de enfermedades relacionadas co
EP1827459A4 (en) THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY ENDURANCE